Myleran (Busulfan)

Busulfan, the active ingredient in Myleran, is an alkylating agent presented as a tablet for oral use. It treats chronic myeloid leukemia, acute myeloid leukemia, and is used in conditioning regimens for bone marrow transplantation.

GNH USA supplies Myleran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Busulfan is an alkylating antineoplastic agent used in several hematologic malignancies and transplant protocols. - Chronic Myeloid Leukemia: helps achieve disease control and remission. - Acute Myeloid Leukemia: contributes to cytoreduction and remission induction. - Conditioning regimen for bone marrow transplantation: provides myeloablation to facilitate donor cell engraftment.

Busulfan may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea and vomiting - Oral mucositis - Diarrhea - Fatigue

Serious or Rare Side Effects: - Hepatic veno‑occlusive disease - Pulmonary fibrosis - Seizures - Severe bone‑marrow suppression (pancytopenia) - Life‑threatening infections

When using Busulfan, careful monitoring and specific precautions are recommended. - Dose adjustment: monitor complete blood counts and adjust dose accordingly. - Liver function: assess hepatic status before and during therapy. - Pulmonary function: evaluate baseline lung function and watch for respiratory symptoms. - Concomitant medications: avoid drugs that lower seizure threshold or significantly alter busulfan metabolism. - Pregnancy: contraindicated (Category D) – avoid use in pregnant patients. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Busulfan interacts with several medicines; some require avoidance, others close monitoring.

Major Interactions (Avoid): - Phenytoin: reduces busulfan exposure, risking treatment failure. - Azole antifungals (e.g., fluconazole, itraconazole): increase busulfan plasma levels, heightening toxicity. - Chloral hydrate: potentiates central nervous system depression and toxicity.

Moderate Interactions (Monitor Closely): - Acetaminophen: may affect hepatic metabolism of busulfan. - Other alkylating agents: additive myelosuppression risk. - Radiotherapy: combined use can increase tissue toxicity.